

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



DINGDANG HEALTH TECHNOLOGY GROUP LTD.
叮嚙健康科技集團有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 09886)

APPOINTMENT OF EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Dingdang Health Technology Group Ltd. (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) announces that Mr. Yang Yibin (楊益斌) (“**Mr. Yang**”) has been appointed as an executive Director with effect from August 25, 2023.

The biographical detail of Mr. Yang is set out as follows:

Mr. Yang, aged 35, is one of the co-founders and a member of the controlling shareholders group of the Company. Mr. Yang has been the general manager of Dingdang Medicine Express Technology Group Ltd., which is a holding company of all the other consolidated affiliated entities of the Group and deputy director of Kuaiyi Department (快醫事業部) since September 2014, and he is mainly responsible for the daily management and in charge of the development of Internet hospital and online medical consultation businesses, including the application of innovative technology and business exploration of key clients. Previously, Mr. Yang also served as the manager and senior manager of the Asset Operation Department, the senior manager of the Product Operation Center and the head of the e-commerce and innovation business of Renhe (Group) Development Co., Ltd. from March 2010 to September 2014.

Mr. Yang is a son of Mr. Yang Wenlong, the chairman of the Board, the president, an executive Director and the controlling shareholder of the Company.

Mr. Yang has entered into a service contract with the Company for an initial term of three years with effect from August 25, 2023, which may be terminated by not less than 3 months’ notice in writing served by either party on the other. Mr. Yang will hold office until the first annual general meeting of the Company after his appointment and be eligible for re-election in accordance with the articles of association of the Company. Mr. Yang does not receive any director’s fees as a Director, but is entitled to receive an annual remuneration of no more than RMB980,000 for his specific management positions in the Group (but is subject to adjustment upon the approval by the Board). He may also additionally receive share- or cash-based bonus, which is subject to the determination by the Board based on the recommendations of the remuneration committee of the Company, taking into account his performance assessment results, the operation and financial results of the Company and the market rate for his positions.

As at the date of this announcement, Mr. Yang was deemed to be interested in an aggregate of 660,205,360 shares of the Company (the “**Shares**”) and underlying Shares, representing approximately 49.21% of the total issued Shares of the Company. within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”). Mr. Yang is a member of the controlling shareholders group of the Company.

Save as disclosed above, as at the date of this announcement, Mr. Yang does not (a) hold any directorships in any other listed public companies in Hong Kong or overseas in the last three years preceding the date of his appointment, (b) hold any other major appointments and professional qualifications, (c) hold any other position with the Company or any members of the Group, (d) have any relationships with any Director, senior management, substantial shareholder or controlling shareholder of the Company and (e) have any interest in any Shares or underlying Shares within the meaning of Part XV of the SFO.

Save as disclosed above, there is no other matters which need to be brought to the attention of the shareholders of the Company regarding the appointment of Mr. Yang or any other information which is required to be disclosed pursuant Rule 13.51(2)(h) to 13.51(2)(v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Board would like to take this opportunity to express its warm welcome to Mr. Yang for joining the Board.

By order of the Board
DINGDANG HEALTH TECHNOLOGY GROUP LTD.
YANG WENLONG
Chairman

Hong Kong, August 25, 2023

As of the date of this announcement, the executive Directors are Mr. YANG Wenlong, Mr. XU Ning, Mr. YU Lei, Mr. YU Qinglong and Mr. YANG Yibin, the non-executive Director is Ms. CAI Li, and the independent non-executive Directors are Mr. ZHANG Shouchuan, Mr. FAN Zhenhong and Mr. JIANG Shan.